Skip to main content
Top
Published in: Medical Oncology 3/2009

01-09-2009 | Original Paper

Evaluation of galectin-8 expression in thyroid tumors

Authors: S. Savin, D. Cvejić, M. Janković, T. Išić, I. Paunović, S. Tatić

Published in: Medical Oncology | Issue 3/2009

Login to get access

Abstract

The expression of galectin-8 (gal-8) has been shown to be altered during neoplastic transformation of certain cell types. This is the first study aimed to analyze the expression of this protein in normal and pathological human thyroid tissue. A total of 41 archival thyroid tissue samples (5 follicular adenomas, 31 papillary carcinomas, 5 follicular carcinomas) together with 36 adjacent hyperplastic or normal thyroid tissues were analyzed by immunohistochemistry. Galectin-8 was expressed in the majority of papillary carcinomas (27/31; 87%). Positive but weaker staining was also found in some of the follicular thyroid carcinomas (2/5; 40%) and adenomas (2/5; 40%). This protein was not detectable in five normal thyroid tissue samples, whereas hyperplastic areas adjacent to tumor were weakly positive in 9 out of 31cases (29%). High gal-8 immunostaining in papillary thyroid carcinoma indicates that gal-8 may potentially serve as a marker of papillary thyroid carcinoma. However, it does not seem to be helpful in the differential diagnostics of follicular carcinoma and adenoma. Further studies are required to determine biological functions and molecular mechanisms underlying the increased expression of gal-8 protein in thyroid lesions, particularly, in papillary thyroid carcinoma.
Literature
1.
go back to reference Fassina AS, Montesco MC, Ninfo V, Denti P, Masarotto G. Histological evaluation of thyroid carcinomas: reproducibility of the “WHO” classification. Tumori. 1993;79:314–20.PubMed Fassina AS, Montesco MC, Ninfo V, Denti P, Masarotto G. Histological evaluation of thyroid carcinomas: reproducibility of the “WHO” classification. Tumori. 1993;79:314–20.PubMed
4.
go back to reference Fisher S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Lab Pathol Med. 2007;132:359–72. Fisher S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Lab Pathol Med. 2007;132:359–72.
6.
go back to reference Leffler H. Galectins: structure and function—a synopsis. Results Probl Cell Differ. 2001;33:57–83.PubMed Leffler H. Galectins: structure and function—a synopsis. Results Probl Cell Differ. 2001;33:57–83.PubMed
9.
go back to reference Danguy A, Camby I, Kiss R. Galectins and cancer. Biochem Biophys Acta. 2002;1572:285–93.PubMed Danguy A, Camby I, Kiss R. Galectins and cancer. Biochem Biophys Acta. 2002;1572:285–93.PubMed
14.
go back to reference Hadari YR, Eisenstein M, Zakut R. Galectin-8: on the road from structure to function. Trends Glycosci Glycotechnol. 1997;9:103–12. Hadari YR, Eisenstein M, Zakut R. Galectin-8: on the road from structure to function. Trends Glycosci Glycotechnol. 1997;9:103–12.
16.
go back to reference Danguy A, et al. Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. Histol Histopathol. 2001;16:861–8.PubMed Danguy A, et al. Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. Histol Histopathol. 2001;16:861–8.PubMed
18.
go back to reference Bassen R, et al. Expression of Po66-CBP, a type-8 galectin, in different healthy, tumoral and peritumoral tissues. Anticancer Res. 1999;19:5429–33.PubMed Bassen R, et al. Expression of Po66-CBP, a type-8 galectin, in different healthy, tumoral and peritumoral tissues. Anticancer Res. 1999;19:5429–33.PubMed
19.
go back to reference Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815–22.PubMed Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815–22.PubMed
20.
go back to reference Fernandez PL, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol. 1997;181:80–6. doi :10.1002/(SICI)1096-9896(199701)181:1<80::AID-PATH699>3.0.CO;2-E.PubMedCrossRef Fernandez PL, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol. 1997;181:80–6. doi :10.1002/(SICI)1096-9896(199701)181:1<80::AID-PATH699>3.0.CO;2-E.PubMedCrossRef
21.
go back to reference Orlandi F, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3013–20. Orlandi F, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3013–20.
22.
go back to reference Inohara H, et al. Expression of galectin-3 in fine needle aspirates as a differential diagnostic marker between benign and malignant thyroid neoplasms. Cancer. 1999;85:2475–84. doi :10.1002/(SICI)1097-0142(19990601)85:11<2475::AID-CNCR25>3.0.CO;2-1.PubMedCrossRef Inohara H, et al. Expression of galectin-3 in fine needle aspirates as a differential diagnostic marker between benign and malignant thyroid neoplasms. Cancer. 1999;85:2475–84. doi :10.1002/(SICI)1097-0142(19990601)85:11<2475::AID-CNCR25>3.0.CO;2-1.PubMedCrossRef
25.
go back to reference Cvejic D, et al. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res. 1998;18:2637–42.PubMed Cvejic D, et al. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res. 1998;18:2637–42.PubMed
27.
go back to reference Herrmann ME, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med. 2002;126:710–3.PubMed Herrmann ME, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med. 2002;126:710–3.PubMed
Metadata
Title
Evaluation of galectin-8 expression in thyroid tumors
Authors
S. Savin
D. Cvejić
M. Janković
T. Išić
I. Paunović
S. Tatić
Publication date
01-09-2009
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 3/2009
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9122-7

Other articles of this Issue 3/2009

Medical Oncology 3/2009 Go to the issue